论文部分内容阅读
本文对１９９０年１月～１９９５年１２月用顺铂为主的腹腔静脉双路联合化疗治疗中晚期及复发性卵巢癌３８例作回顾性分析。本组共腹腔化疗１１５人次，人均３次；静脉化疗１６９疗程，平均４．５疗程。现存活２６例，其５、３、２年存活率分别为３１．６％、５７．９％、６８．４％。本文探讨了顺铂腹腔治疗的途径、用药剂量、主要毒副反应，认为中晚期及复发卵巢癌的治疗在肿瘤细胞减灭术基础上再以顺铂为主的腹腔静脉双路化疗是一个理想的选择
This article retrospectively analyzed 38 patients with advanced and recurrent ovarian cancer treated with cisplatin-based intra-venous veno-venous chemotherapy from January 1990 to December 1995. This group received a total of 115 intraperitoneal chemotherapy, 3 per capita; 169 courses of intravenous chemotherapy, an average of 4.5 courses. Survival was found in 26 cases. The 5-, 3-, and 2-year survival rates were 31.6%, 57.9%, and 68.4%, respectively. This article discusses the way of cisplatin intraperitoneal treatment, dosage, and main toxicities and side effects. It is considered that the treatment of mid-advanced and recurrent ovarian cancer is based on cytoreductive surgery and then cisplatin-based abdominal venovenous dual chemotherapy is an ideal s Choice